Atoris 30s 20 mg coated tablets

  • $25.50
Sku: fc0417a31da2
Ingredient: Atorvastatin
The instruction for medical use

of ATORIS® medicine

the Trade name
of Atoris®

the International unlicensed

name Atorvastatin Lekarstvennaya
the Tablet form, film coated, 10 mg and 20 mg

One tablet contains
active agent - an atorvastatin of calcium of 10.360 mg (equivalent to an atorvastatin of 10.000 mg) or 20.720 mg (equivalent to an atorvastatin
of 20.000 mg),
excipients: povidone, sodium lauryl sulfate, calcium carbonate, cellulose microcrystalline, lactoses monohydrate, sodium of a kroskarmelloz, magnesium stearate,
structure of a cover: opadray the II HP 85F28751 white: polyvinyl alcohol, titan dioxide (E 171), macrogoal 3000, talc.

of the Tablet of round shape, slightly convex, film coated white color. On cross section the kernel of white color is visible.

Pharmacotherapeutic group
Hypolipidemic drugs. GMG-KoA-reduktazy inhibitors.
The code of automatic telephone exchange C10AA05

the Pharmacological

Pharmacokinetics Absorption properties of an atorvastatin of high, about 80% is soaked up from digestive tract. Time of approach of the maximum concentration (Cmax), on average, 1-2 hours. At women With max is 20% higher, and AUC indicator – is 10% lower. At patients with alcoholic cirrhosis time of achievement of the maximum concentration is 16 times higher than norm. Owing to intensive metabolism at the first passing through a liver bioavailability of an atorvastatin low (12%). The average volume of distribution of an atorvastatin equals 381 l. More than 98% of an atorvastatin contact proteins of blood plasma. Atorvastatin does not get through a blood-brain barrier. It is metabolized mainly in a liver under the influence of P4503A4 cytochrome with formation pharmacological of active metabolites (orto- and parahydroxylated metabolites, beta oxidation products). These are active metabolites which cause about 70% of the inhibiting activity concerning GMG-KoA-reduktazy which remains the 20-30th.
Elimination half-life of an atorvastatin equals to 14 hours. It is removed generally with bile (is not exposed to the significant enterohepatic recirculation, it is not removed during a hemodialysis). About 46% of an atorvastatin are removed with excrements and less than 2% are allocated with urine.
A pharmacodynamics
of Atoris® – hypolipidemic means from group of statines. The main mechanism of action of an atorvastatin is the activity inhibition 3-hydroxy-3-methylglutaryl-coenzyme A - (GMG-KOA-) reductases, the enzyme catalyzing transformation GMG-KoA into mevalonovy acid. This transformation is one of early stages in a chain of synthesis of cholesterol in an organism. Suppression atorvastatiny synthesis of cholesterol results in hyperreactivity of receptors of LDL (lipoproteins of low density) in a liver and also in extrahepatic fabrics. These receptors connect particles of LDL and delete them from blood plasma that leads to decrease in level of LDL cholesterol in blood.
The anti-sclerous effect of Atorisa® is a consequence of impact of drug on walls of vessels and components of blood. Drug suppresses synthesis of the isoprenoids which are growth factors of cells of an internal cover of vessels. Under the influence of an atorvastatin the endothelium - dependent expansion of blood vessels improves. Аторис® reduces the content of cholesterol, lipoproteins of low density, apolipoprotein B, triglycerides. Causes increase in content of LPVP cholesterol (lipoproteins of high density) and apolipoprotein A.
As a rule, action of Atorisa® develops after two weeks of administration of drug, and the maximum effect is reached in four weeks.

a lipidemia (primary lipidemia (IIa and IIb type), including
a polygenic hypercholesterolemia)
- a heterozygous and homozygous family hypercholesterolemia

the Route of administration and doses
Prior to treatment of the patient by Atoris has to be transferred to the diet providing decrease in maintenance of lipids in blood which needs to be observed during therapy by drug.
The drug is taken inside, on an empty stomach or after a meal.
The dose of drug varies from 10 mg to 80 mg of 1 times/days. The dose of drug is selected taking into account the LPNP initial level, by the purposes of therapy and individual therapeutic effect.
Atoris can be accepted once at any time, but at the same time every day. The essential therapeutic effect is noted after two weeks of treatment, and the maximum effect develops in four weeks. Therefore the dosage should not be changed earlier, than in four weeks after the beginning of administration of drug in the previous dose. Duration of administration of drug depends on indicators of a lipidic range of blood and degree of risk of complications of cardiovascular diseases.
Primary (heterozygous hereditary and polygenic) the hypercholesterolemia (type of Pa) and the mixed lipidemia (Pb type)
Treatment begins with the recommended initial dose which is increased after four weeks depending on reaction of the patient. The maximum daily dose makes 80 mg.
A homozygous hereditary hypercholesterolemia
the Range of doses same, as well as at other types of a lipidemia. The initial dose is selected individually depending on severity of a disease. At most of patients with a homozygous hereditary hypercholesterolemia the optimum effect was observed when using drug in a daily dose of 80 mg (once). Atoris is used as additional therapy to other methods of treatment (plasma exchange) or as the main treatment if therapy by means of other methods is impossible.
At elderly people and at patients with diseases of kidneys of a dose of Atoris it is not necessary to change.
At patients with abnormal liver functions the care in connection with delay of removal of drug from an organism is necessary. In a similar situation it is necessary to control carefully clinical and laboratory indicators and at identification of significant pathological changes the dose has to be reduced or treatment has to be stopped

Side effects
- allergic reactions
- a headache, insomnia, dizziness, paresthesia
- a stethalgia
- intestinal impassability, a meteorism, indigestion, nausea,
- skin rash, an itching
- myalgia, an arthralgia, a back pain
- an asthenia
- increase in level of a creatine kinase in blood
- thrombocytopenia
- anorexia
- impotence
- amnesia
- peripheral neuropathy
- vomiting, pancreatitis
- urticaria
- a myopathy
- discomfort, increase in body weight
- muscle weakness
- increase in level of transaminases (ALT, nuclear heating plant) in blood serum
is rare:
- hepatitis, cholestatic jaundice
- miozita, a rhabdomyolysis
Very seldom
- anafalaktichesky reactions
- a Quincke's disease, an alopecia, bullous rash (multiformny
erythema, Stephens-Johnson's syndrome, a toxic epidermal
- increase or lowering of the level of sugar in blood
For some side effects classified as is 'very rare', the causal relationship with drug is not proved.
Increase in level of transaminases of blood serum were dependent on a dose and are reversible for all patients.
Increase in level of a kreatininkinaza more than by 10 times from an allowable limit, is noted at 0.4% of patients, 0.1% of these patients had muscular pains, symptoms of a tendinitis or weakness.
There are single messages about the following side effects of some statines:
- sleep disorders, including insomnia and nightmares
- memory loss
- sexual difficulties
- a depression
- exceptional cases of an intermediate disease of lungs, especially at
long-term therapy

of the Contraindication
- hypersensitivity to any of drug components
- liver diseases in an active stage (including. active chronic
hepatitis, chronic alcoholic hepatitis), a liver failure,
cirrhosis of any etiology, increase in activity of hepatic
transaminases of not clear genesis
- deficiency of lactase, a galactosemia or a sprue of a galactose -
- a disease of skeletal muscles
- pregnancy and the period of a lactation
- children's age up to 18 years (the efficiency and safety of use
is not established)

Medicinal interactions
Simultaneous use of an atorvastatin with cyclosporine, antibiotics (erythromycin, klaritromitsin, kvinupristin/dalfopristin), protease HIV inhibitors (indinavir, ritonavir), antifungal means (flukonazol, itrakonazol, ketokonazol) or with nefazadony can lead to increase in maintenance of an atorvastatin in blood serum that increases risk of emergence of a myopathy with a rhabdomyolysis and a renal failure. Similar interaction is possible at the combined reception of Atorisa® with derivatives of fibroyevy acid and Niacinum.
The concomitant use of an atorvastatin with Phenytoinum can lead to reduction of efficiency of an atorvastatin. At joint reception, antacids (suspension of magnesium hydroxides and aluminum) reduce the maintenance of an atorvastatin in blood plasma. At a concomitant use of an atorvastatin with kolestipoly, concentration of an atorvastatin in plasma goes down for 25%, but the therapeutic effect of a combination is higher, than effect of one atorvastatin.
At the patients who are at the same time receiving 80 mg of an atorvastatin and digoxin, digoxin content in plasma increases approximately by 20%. The patients receiving atorvastatin with digoxin should be observed.
At joint reception of an atorvastatin with oral contraceptives (combination of norethindrone and ethinylestradiol) strengthening of absorption of contraceptives and increase in their concentration in blood plasma is possible. It is necessary to control the choice of contraceptives at the women receiving atorvastatin.
The concomitant use of an atorvastatin with warfarin can strengthen in the first days effect of warfarin on fibrillation indicators (reduction of a prothrombin time). This effect disappears after 15 days of joint intake of the specified drugs.
The grapefruit juice use during treatment of Atorisom® can lead to increase in concentration of drug in blood plasma. In this regard the patients accepting Atoris® have to avoid the use of this juice.

The special
instructions Therapy of Atorisom® does not cancel a standard gipokholesterinemichesky diet which he has to observe during the entire period of treatment.
Increase in activity of hepatic enzymes in blood serum can be observed during treatment of Atorisom®. This increase, as a rule, small has also no clinical value. However control of activity of hepatic enzymes in blood serum before treatment, in 6 weeks, 12 weeks is recommended and at increase in a dose of an atorvastatin. If it is noted triple, rather upper bounds of norm, increase in activity of aspartate aminotransferase (nuclear heating plant) and/or alaninaminotranspherase (ALT), treatment of Atorisom® has to be stopped. Аторис® can cause increase in activity of a kreatinfosfokinaza and aminotransferases.
At the women of reproductive age who are not using reliable contraception, use of Atorisa® is not recommended. If the patient plans pregnancy, it has to stop Atoris's reception at least a month before the planned pregnancy.
Treatment of Atorisom® can cause a myopathy which sometimes is followed by the rhabdomyolysis leading to an acute renal failure. The risk of this complication increases at a concomitant use with Atorisom® of one or several of the following medicines: derivatives of fibroyevy acid, Niacinum, cyclosporine, nefazadon, some antibiotics, antifungal means from group of 'azoles', HIV inhibitors - proteases.
Patients who take essential amount of alcohol or having a case history of a liver have to take Atoris® with caution.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
during treatment needs to be careful during the driving of motor transport and occupation other potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions.

Symptoms: strengthening of manifestations of side effects of drug.
Treatment: monitoring and maintenance of vital signs and prevention of further absorption of drug (gastric lavage, intake of activated carbon or depletive).
At development of a myopathy with the subsequent rhabdomyolysis and an acute renal failure (rare, but heavy side effect) drug has to be immediately cancelled, and the patient needs to enter diuretic and solution of Natrii hydrocarbonas. If necessary it is necessary to carry out a hemodialysis. The rhabdomyolysis can lead to a hyperpotassemia which elimination requires intravenous administration of Calcii chloridum or calcium of a gluconate, infusion of glucose with insulin, use of exchangers of potassium ions or, in hard cases, carrying out a hemodialysis.

The form of release and packing
of the Tablet, film coated, 10 mg and 20 mg
On 10 tablets place in blister strip packaging from a film of OPA/Al/PVC and aluminum foil.
On 1, 3 or 9 blister strip packagings together with the instruction for use in the state and Russian languages place in a pack from cardboard.

To Store storage conditions at a temperature not over 25 ºС.
To store out of children's reach!

2 years
not to apply a period of storage after a period of storage.

Prescription status
According to the prescription

the Producer
of KRK, of. The place is new, Slovenia
Shmaryeshka 6, 8501 the place, Slovenia

the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods)
Representation KRKA, tovarna zdravil, d.d., Novo mesto in PK
PK, 050059, Almaty, Al-Farabi Ave., 5/1, section 3 A, the 4th floor Is new.
ph. 8 (727) 311-08-09
fax 8 (727) 311-08-12
to Develop
Write a review
Related Products
Rosustar 30s 10 mg film-coated tablets
Polpharma (Poland)
Simvasterol 28's 40 mg coated tablets
Egis (Hungary)
Egilok® (Metoprolol) 25 mg, 60 tablets
VIVA Pharm (Kazakhstan)
Bisoprolol Viva Pharm 30s 10 mg coated tablets
Ferrer (Spain)
Britomar 30s 5 mg sustained-release tablets
Gedeon Richter (Hungary)
Pananginum (50 coated tablets)
FDP Medlac powder with solvent 5 g
Medlac Pharma Italy Co., Ltd. (Vietnam)
FDP Medlac powder with solvent 5 g
$39.00 $46.40
Evalar (Russia)
Dihydroquercetin 25 mg (20 tablets)